Detailed definition
Fulvestrant (Faslodex) is the first FDA-approved SERD, indicated for HR-positive HER2-negative advanced or metastatic breast cancer. It is administered as monthly intramuscular injections at 500 mg. Mechanism: fulvestrant binds the estrogen receptor with high affinity and induces conformational changes that target the receptor for proteasomal degradation, producing a more complete antagonism than SERMs. It is often combined with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) for advanced disease.
Why it matters in menopause
Fulvestrant is an oncology agent, not a menopause therapy, but women on it experience profound estrogen-deprivation symptoms similar to or worse than aromatase inhibitor therapy. Non-hormonal symptom management is essential.
Related terms
Sources
External references: Wikipedia.